Dermatology Medical News about malignant melanoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma
Cancer, 09/09/09

Glaspy J et al. – Despite the occurrence of treatment–related serious adverse events, ~80% of patients continued treatment. The higher dose of lenalidomide did not improve response rate, time to progression, or OS of patients with relapsed/refractory stage IV melanoma. A parallel placebo–controlled study has been conducted to further assess the efficacy of lenalidomide in stage IV melanoma patients.

<< Previous
Expression pattern of GATA-3 in embryonic and fetal human skin...

Next >>
Sliding economy leaves physicians wary about collections

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Cancer, 10/30/09 Relevance Score: 69%

Analysis of Globule Types in Malignant Melanoma
Archives of Dermatology, 11/17/09 Relevance Score: 68%

Ground-glass nodules found in two patients with malignant melanomas: different growth rate and different histology
Clinical Imaging, 11/17/09 Relevance Score: 68%

Unusual variants of malignant melanoma
Clinics in Dermatology, 11/06/09 Relevance Score: 67%

Patterns of GRP78 and MTJ1 expression in primary cutaneous malignant melanoma
Modern Pathology, 10/23/09 Relevance Score: 67%